444 results on '"Tyrosine -- Intellectual property"'
Search Results
2. 'Pyrimidinyl Tyrosine Kinase Inhibitors' in Patent Application Approval Process (USPTO 20240417389)
3. Patent Issued for Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer (USPTO 12083112)
4. 'Agonists Of Epha And Their Uses' in Patent Application Approval Process (USPTO 20240287049)
5. 'Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof' in Patent Application Approval Process (USPTO 20240262932)
6. Patent Application Titled 'Amino Heteroaryl Compounds And Compositions' Published Online (USPTO 20240246944)
7. Researchers Submit Patent Application, 'Quinazoline-Based Compound, Composition, And Application Of Quinazoline-Based Compound', for Approval (USPTO 20240246934)
8. Patent Application Titled 'Therapeutic Targeting Of Receptor Tyrosine Kinase Inhibitor-Induced Androgen Receptor Phosphorylation In Cancer' Published Online (USPTO 20240165078)
9. Researchers Submit Patent Application, 'Pyrimidines For Degrading Bruton'S Tyrosine Kinase', for Approval (USPTO 20240109877)
10. Patent Application Titled 'Heteroaromatic Compounds And Uses Thereof' Published Online (USPTO 20240092774)
11. Patent Issued for Human PAH expression cassette for treatment of PKU by liver-directed gene replacement therapy (USPTO 12173308)
12. Patent Application Titled 'Inhibitors Of Tyk2' Published Online (USPTO 20240425484)
13. Patent Issued for Substituted piperazines as BTK inhibitors (USPTO 12173008)
14. Patent Issued for Pyrimidines for degrading Bruton's tyrosine kinase (USPTO 12172992)
15. Researchers Submit Patent Application, 'crystalline Form of (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, Preparation, And Uses Thereof', for Approval (uspto 20240409546)
16. Patent Issued for Anti-MERTK agonistic antibodies and uses thereof (USPTO 12162942)
17. Patent Issued for Purification process for removal of tyrosine sulfation antibody variants; purified compositions (USPTO 12162938)
18. Patent Issued for Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R (USPTO 12162858)
19. Patent Issued for Macrocyclic inhibitors of ALK, TRKA, TRKB, and ROS1 (USPTO 12157738)
20. Researchers Submit Patent Application, 'Heteroaryl Heterocyclic Compounds And Uses Thereof', for Approval (USPTO 20240398791)
21. 'Multi-Targeted Tyrosine Kinase Inhibitors Effective In Antitumor Uses' in Patent Application Approval Process (USPTO 20240383858)
22. Patent Application Titled 'Sulfoximine Compound And Use Thereof' Published Online (USPTO 20240376093)
23. Patent Issued for Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof (USPTO 12129266)
24. Patent Application Titled 'Masked Chimeric Antigen Receptor Specific To Tyrosine-Protein Kinase Like 7 (Ptk7) And Immune Cells Expressing Such' Published Online (USPTO 20240352151)
25. Patent Issued for Inhibiting agents for bruton's tyrosine kinase (USPTO 11858926)
26. Patent Issued for Agonists of EPHA and their uses (USPTO 11814372)
27. New Findings in Cancer Described from Shiraz University of Medical Sciences (A Patent Review On Efficient Strategies for the Total Synthesis of Pazopanib, Regorafenib and Lenvatinib As Novel Anti-angiogenesis Receptor Tyrosine Kinase Inhibitors ...)
28. Patent Issued for Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (USPTO 12103931)
29. Patent Issued for Substituted pyrazines as inhibitors of BTK, and mutants thereof (USPTO 12086788)
30. Patent Application Titled 'Salt And Crystal Forms Of An Epidermal Growth Factor Receptor Inhibitor' Published Online (USPTO 20240293404)
31. Patent Issued for Multi-targeted tyrosine kinase inhibitors effective in antitumor uses (USPTO 12071408)
32. Patent Issued for Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitors (USPTO 12070457)
33. 'Naphthyridone Compounds For Inhibition Of Raf Kinases And/Or Bcr-Abl Tyrosine Kinases' in Patent Application Approval Process (USPTO 20240287062)
34. 'Compounds For Targeting Degradation Of Bruton'S Tyrosine Kinase' in Patent Application Approval Process (USPTO 20240287076)
35. 'Receptor Tyrosine Kinase Agonist, Composition For Cell Culture Medium, And Undifferentiated Maintenance Composition' in Patent Application Approval Process (USPTO 20240279618)
36. Researchers Submit Patent Application, 'Cyp76ad1-Beta Clade Polynucleotides, Polypeptides, And Uses Thereof', for Approval (USPTO 20240263202)
37. Patent Application Titled 'Bruton'S Tyrosine Kinase Inhibitors' Published Online (USPTO 20240246988)
38. Patent Application Titled 'Dosing Regimens' Published Online (USPTO 20240245666)
39. Patent Application Titled 'Drug Formulations Of ®-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1h-Imidazo[4,5-C]pyridin-2(3h)-One' Published Online (USPTO 20240238267)
40. Researchers Submit Patent Application, 'Erbb/Btk Inhibitors', for Approval (USPTO 20230293535)
41. 'Quinazoline Derivatives As Antitumor Agents' in Patent Application Approval Process (USPTO 20230293533)
42. Patent Application Titled 'Pyrimidinyl Tyrosine Kinase Inhibitors' Published Online (USPTO 20230174511)
43. 'Amide Compounds And Uses Thereof' in Patent Application Approval Process (USPTO 20230174513)
44. Patent Issued for 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (USPTO 11660303)
45. 'Tyk-2 Inhibitor' in Patent Application Approval Process (USPTO 20230159520)
46. Researchers Submit Patent Application, 'Inhibiting Agents For Bruton'S Tyrosine Kinase', for Approval (USPTO 20230147490)
47. Patent Application Titled 'N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases' Published Online (USPTO 20230142839)
48. 'Use Of Quinazoline-Based Tyrosine Kinase Inhibitors For The Treatment Of Cancers With Nrg1 Fusions' in Patent Application Approval Process (USPTO 20230121116)
49. Patent Issued for Human monoclonal antibodies specific for FLT3 and uses thereof (USPTO 12012455)
50. Patent Application Titled 'Combination Therapies With Bispecific Anti-Egfr/C-Met Antibodies And Third Generation Egfr Tyrosine Kinase Inhibitors' Published Online (USPTO 20240199748)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.